Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Coherus Oncology (CHRS) over the last 12 years, with Q3 2025 value amounting to $2000.0.

  • Coherus Oncology's Cash from Financing Activities rose 10119.76% to $2000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$281.6 million, marking a year-over-year decrease of 5069.39%. This contributed to the annual value of -$187.0 million for FY2024, which is 36864.08% down from last year.
  • Per Coherus Oncology's latest filing, its Cash from Financing Activities stood at $2000.0 for Q3 2025, which was up 10119.76% from -$281.5 million recorded in Q2 2025.
  • Over the past 5 years, Coherus Oncology's Cash from Financing Activities peaked at $54.3 million during Q2 2023, and registered a low of -$281.5 million during Q2 2025.
  • For the 5-year period, Coherus Oncology's Cash from Financing Activities averaged around -$15.4 million, with its median value being $887000.0 (2024).
  • In the last 5 years, Coherus Oncology's Cash from Financing Activities surged by 743467.41% in 2023 and then crashed by 44592.73% in 2024.
  • Over the past 5 years, Coherus Oncology's Cash from Financing Activities (Quarter) stood at $1.5 million in 2021, then soared by 343.38% to $6.6 million in 2022, then crashed by 94.45% to $366000.0 in 2023, then crashed by 36.89% to $231000.0 in 2024, then tumbled by 99.13% to $2000.0 in 2025.
  • Its Cash from Financing Activities was $2000.0 in Q3 2025, compared to -$281.5 million in Q2 2025 and -$264000.0 in Q1 2025.